21042 |
03/01/2021 |
BANZEL 40 MG/ML ORAL ORAL SUSP |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
RUFINAMIDE 40 MG/ML ORAL ORAL SUSP-5 |
21042 |
05/01/2021 |
RANITIDINE HCL 15 MG/ML ORAL SYRUP |
DELETION OF DRUG FROM FORMULARY |
REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL |
|
21042 |
05/01/2021 |
RANITIDINE HCL 150 MG ORAL TABLET |
DELETION OF DRUG FROM FORMULARY |
REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL |
|
21042 |
05/01/2021 |
RANITIDINE HCL 25 MG/ML INJECTION VIAL |
DELETION OF DRUG FROM FORMULARY |
REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL |
|
21042 |
05/01/2021 |
RANITIDINE HCL 300 MG ORAL TABLET |
DELETION OF DRUG FROM FORMULARY |
REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL |
|
21042 |
05/01/2021 |
RANITIDINE HCL 50 MG/2 ML INJECTION VIAL |
DELETION OF DRUG FROM FORMULARY |
REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL |
|
21042 |
03/01/2021 |
SAPHRIS 10 MG SUBLINGUAL TAB SUBL |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
ASENAPINE MALEATE 10 MG SUBLINGUAL TAB SUBL-2 |
21042 |
03/01/2021 |
SAPHRIS 2.5 MG SUBLINGUAL TAB SUBL |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
ASENAPINE MALEATE 2.5 MG SUBLINGUAL TAB SUBL-2 |
21042 |
03/01/2021 |
SAPHRIS 5 MG SUBLINGUAL TAB SUBL |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
ASENAPINE MALEATE 5 MG SUBLINGUAL TAB SUBL-2 |
21042 |
03/01/2021 |
TECFIDERA 120-240 MG ORAL CAPSULE DR |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
DIMETHYL FUMARATE 120-240 MG ORAL CAPSULE DR-5 |
21042 |
05/01/2021 |
BETHKIS 300 MG/4ML INHALATION AMPUL-NEB |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
TOBRAMYCIN 300 MG/4ML INHALATION AMPUL-NEB-5 |
21042 |
05/01/2021 |
DEMSER 250 MG ORAL CAPSULE |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
METYROSINE 250 MG ORAL CAPSULE-5 |
21042 |
05/01/2021 |
SYMFI LO 400-300 MG ORAL TABLET |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
EFAVIRENZ-LAMIVU-TENOFOV DISOP 400-300 MG ORAL TABLET-5 |
21042 |
05/01/2021 |
ATRIPLA 600-200MG ORAL TABLET |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
EFAVIRENZ-EMTRIC-TENOFOV DISOP 600-200MG ORAL TABLET-5 |
21042 |
05/01/2021 |
SYMFI 600-300MG ORAL TABLET |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
EFAVIRENZ-LAMIVU-TENOFOV DISOP 600-300MG ORAL TABLET-5 |
21042 |
05/01/2021 |
KUVAN 100 MG ORAL TABLET SOL |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
SAPROPTERIN DIHYDROCHLORIDE 100 MG ORAL TABLET SOL-5 |
21042 |
05/01/2021 |
EMTRIVA 200 MG ORAL CAPSULE |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
EMTRICITABINE 200 MG ORAL CAPSULE-2 |
21042 |
05/01/2021 |
FERRIPROX 500 MG ORAL TABLET |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
DEFERIPRONE 500 MG ORAL TABLET-5 |
21042 |
05/01/2021 |
TECFIDERA 120 MG ORAL CAPSULE DR |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
DIMETHYL FUMARATE 120 MG ORAL CAPSULE DR-5 |
21042 |
05/01/2021 |
TECFIDERA 240 MG ORAL CAPSULE DR |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
DIMETHYL FUMARATE 240 MG ORAL CAPSULE DR-5 |
21042 |
05/01/2021 |
TYKERB 250 MG ORAL TABLET |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
LAPATINIB 250 MG ORAL TABLET-5 |
21042 |
05/01/2021 |
TRUVADA 200-300 MG ORAL TABLET |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
EMTRICITABINE-TENOFOVIR DISOP 200-300 MG ORAL TABLET-5 |
21042 |
02/27/2021 |
ALINIA 500 MG ORAL TABLET |
BRAND DELETION, ADD FRF GENERIC |
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
NITAZOXANIDE 500 MG ORAL TABLET-5 |